The lack of awareness about rare diseases like prurigo nodularis and available treatment options is anticipated to impede market growth.

TD Cowen analyst Stacy Ku maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price target of $5.00. The ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

VYNE Therapeutics Inc., a Delaware-based pharmaceutical company specializing in immuno-inflammatory conditions, recently made key updates in its corporate presentation. On January 13, 2025 ...

VYN-201 is under clinical development by VYNE Therapeutics and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs for Vitiligo have a 42% phase transition success rate (PTSR) ...

Menlo Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, associated with dermatologic conditions such as ...